Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.56 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357197 | 1.00 | HCRTR1 (0.56) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL13070464 | 0.95 | USP30 (0.52) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL2707200 | 0.95 | USP30 (0.52) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL18462768 | 0.95 | USP30 (0.52) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL2706118 | 0.95 | USP30 (0.52) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL14985689 | 0.94 | HCRTR1 (0.51) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL2707183 | 0.94 | HCRTR1 (0.51) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL204876 | 0.94 | HCRTR1 (0.51) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL12075567 | 0.94 | HCRTR1 (0.54) | HCRTR1HCRTR2CHEK2 | |
| SCHEMBL204028 | 0.92 | HCRTR1 (0.58) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-16 | — | — | US | disclosed |
| US-8618153-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130012540-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-10 | — | — | US | disclosed |
| EP-2499132-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20110281910-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-17 | — | — | US | disclosed |
| WO-2011060000-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281910-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | HCRTR1 4555/4885HCRTR2 4665/4885USP30 1786/4885 |
| US-20130012540-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | HCRTR1 4555/4885HCRTR2 4665/4885USP30 1786/4885 |
| US-20140018389-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | HCRTR1 4555/4885HCRTR2 4665/4885USP30 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.